Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas
A phase 2 trial of Camrelizumab, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by CrystalGenomics, Inc., now recruiting.
Overview
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05841472 by CrystalGenomics, Inc., with 60 participants planned, started 2023-08-23 and due to reach its primary completion in 2026-08. Interventions recorded: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin. Conditions listed: Non Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialCameL
Shares Camrelizumab, Pemetrexed, Carboplatin, Non-small-cell lung cancer.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialDZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.